FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Mangal Compusolution IPO and Onyx Biotec IPO.
Mangal Compusolution IPO is a SME Book Built Issue IPO proposed to list at BSE SME while Onyx Biotec IPO is a SME Book Built Issue proposed to list at NSE SME.
Mangal Compusolution IPO | Onyx Biotec IPO | |
---|---|---|
Logo | ||
Issue Category | SME | SME |
Issue Type | IPO | IPO |
Process Type | Fixed Price Issue | Book Built Issue |
Listing At | BSE SME | NSE SME |
Lead Managers | Jawa Capital Services Private Limited | Horizon Management Private Limited |
Registrar | Kfin Technologies Limited | Mas Services Limited |
Market Maker | Rikhav Securities Limited | Giriraj Stock Broking Private Limited |
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | Anchor Investor | |
IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Mangal Compusolution IPO is up to ₹16.23 Cr whereas the issue size of the Onyx Biotec IPO is up to ₹29.34 Cr. The final issue price of Mangal Compusolution IPO is ₹45.00 per share and of Onyx Biotec IPO is ₹61.00 per share.
Mangal Compusolution IPO | Onyx Biotec IPO | |
---|---|---|
Face Value | ₹10 per share | ₹10 per share |
Issue Price (Lower) | ₹58.00 per share | |
Issue Price (Upper) | ₹61.00 per share | |
Issue Price (Final) | ₹45.00 per share | ₹61.00 per share |
Discount (Retail) | ||
Discount (Employee) | ||
Market Lot Size | 3000 shares | 2000 shares |
Fresh Issue Size | 36,06,000 shares | 48,10,000 shares |
Fresh Issue Size (Amount) | up to ₹16.23 Cr | up to ₹29.34 Cr |
OFS Issue Size | ||
OFS Issue Size (Amount) | ||
Issue Size Total | 36,06,000 shares | 48,10,000 shares |
Issue Size Total (Amount) | up to ₹16.23 Cr | up to ₹29.34 Cr |
Mangal Compusolution IPO opens on Nov 12, 2024, while Onyx Biotec IPO opens on Nov 13, 2024. The closing date of Mangal Compusolution IPO and Onyx Biotec IPO is Nov 14, 2024, and Nov 18, 2024, respectively.
Mangal Compusolution IPO | Onyx Biotec IPO | |
---|---|---|
Anchor Bid Date | Nov 12, 2024 | |
Issue Open | Nov 12, 2024 | Nov 13, 2024 |
Issue Close | Nov 14, 2024 | Nov 18, 2024 |
Basis Of Allotment (Tentative) | Nov 18, 2024 | Nov 19, 2024 |
Initiation of Refunds (Tentative) | Nov 19, 2024 | Nov 20, 2024 |
Credit of Share (Tentative) | Nov 19, 2024 | Nov 20, 2024 |
Listing date (Tentative) | Nov 21, 2024 | Nov 22, 2024 |
Anchor Lockin End date 1 | Dec 19, 2024 | |
Anchor Lockin End date 2 | Feb 17, 2025 |
Mangal Compusolution IPO P/E ratio is 11.66, as compared to Onyx Biotec IPO P/E ratio of 26.81.
Mangal Compusolution IPO | Onyx Biotec IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial | Mangal Compusolution Limited Financial Information (Restated)Mangal Compusolution Limited's revenue decreased by -32.69% and profit after tax (PAT) dropped by -45.21% between the financial year ending with March 31, 2024 and March 31, 2023.
|
Onyx Biotec Limited Financial Information (Restated)Onyx Biotec Limited's revenue increased by 35.99% and profit after tax (PAT) rose by 64.35% between the financial year ending with March 31, 2024 and March 31, 2023.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 100.00% | 88.60% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | 73.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P/E Ratio | 11.66 | 26.81 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Market Cap | ₹61.23 Cr. | ₹110.61 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROE | 3.97%% | 4.99%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROCE | 2.05%% | 3.71%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt/Equity | 0.9 | 1.21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EPS | ₹3.86 | ₹2.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RoNW | 15.56%% | 4.99%% |
In the Mangal Compusolution IPO retail investors (RII) are offered 17,10,000 shares while in Onyx Biotec IPO retail investors are offered 17,10,000 shares. Qualified institutional buyers (QIB) are offered 0 shares in Mangal Compusolution IPO and 9,12,000 shares in Onyx Biotec IPO.
Mangal Compusolution IPO | Onyx Biotec IPO | |
---|---|---|
Anchor Investor Reserveration | 13,66,000 shares | |
Market Maker Reserveration | 1,86,000 shares | 2,44,000 shares |
QIB | 0 shares | 9,12,000 shares |
NII | 17,10,000 shares | 6,88,000 shares |
RII | 17,10,000 shares | 16,00,000 shares |
Employee | 0 shares | 0 shares |
Others | ||
Total | 34,20,001 shares | 32,00,000 shares |
Mangal Compusolution IPO subscribed 34.59x in total, whereas Onyx Biotec IPO subscribed 198.00x.
Mangal Compusolution IPO | Onyx Biotec IPO | |
---|---|---|
QIB (times) | 32.49x | |
NII (times) | 22.28x | 602.86x |
Big NII (times) | ||
Small NII (times) | ||
RII (times) | 46.91x | 118.26x |
Employee (times) | ||
Other (times) | ||
Total (times) | 34.59x | 198.00x |
Add a public comment...
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|